279 related articles for article (PubMed ID: 22496609)
1. Autism spectrum disorders: is mesenchymal stem cell personalized therapy the future?
Siniscalco D; Sapone A; Cirillo A; Giordano C; Maione S; Antonucci N
J Biomed Biotechnol; 2012; 2012():480289. PubMed ID: 22496609
[TBL] [Abstract][Full Text] [Related]
2. Involvement of dietary bioactive proteins and peptides in autism spectrum disorders.
Siniscalco D; Antonucci N
Curr Protein Pept Sci; 2013 Dec; 14(8):674-9. PubMed ID: 24106964
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders.
Siniscalco D; Sapone A; Giordano C; Cirillo A; de Magistris L; Rossi F; Fasano A; Bradstreet JJ; Maione S; Antonucci N
J Autism Dev Disord; 2013 Nov; 43(11):2686-95. PubMed ID: 23585028
[TBL] [Abstract][Full Text] [Related]
4. Possible use of Trichuris suis ova in autism spectrum disorders therapy.
Siniscalco D; Antonucci N
Med Hypotheses; 2013 Jul; 81(1):1-4. PubMed ID: 23597946
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal stem cells in treating autism: Novel insights.
Siniscalco D; Bradstreet JJ; Sych N; Antonucci N
World J Stem Cells; 2014 Apr; 6(2):173-8. PubMed ID: 24772244
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of fetal stem cell transplantation in autism spectrum disorders: an open-labeled pilot study.
Bradstreet JJ; Sych N; Antonucci N; Klunnik M; Ivankova O; Matyashchuk I; Demchuk M; Siniscalco D
Cell Transplant; 2014; 23 Suppl 1():S105-12. PubMed ID: 25302490
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008.
;
MMWR Surveill Summ; 2012 Mar; 61(3):1-19. PubMed ID: 22456193
[TBL] [Abstract][Full Text] [Related]
8. Perspectives on the use of stem cells for autism treatment.
Siniscalco D; Bradstreet JJ; Sych N; Antonucci N
Stem Cells Int; 2013; 2013():262438. PubMed ID: 24222772
[TBL] [Abstract][Full Text] [Related]
9. Rational use of mesenchymal stem cells in the treatment of autism spectrum disorders.
Liu Q; Chen MX; Sun L; Wallis CU; Zhou JS; Ao LJ; Li Q; Sham PC
World J Stem Cells; 2019 Feb; 11(2):55-72. PubMed ID: 30842805
[TBL] [Abstract][Full Text] [Related]
10. Cell Therapy Targets for Autism Spectrum Disorders: Hopes, Challenges and Future Directions.
Larijani B; Foroughi Heravani N; Alavi-Moghadam S; Goodarzi P; Rezaei-Tavirani M; Payab M; Gholami M; Razi F; Arjmand B
Adv Exp Med Biol; 2021; 1341():107-124. PubMed ID: 32072476
[TBL] [Abstract][Full Text] [Related]
11. Stem cell therapy in autism: recent insights.
Siniscalco D; Kannan S; Semprún-Hernández N; Eshraghi AA; Brigida AL; Antonucci N
Stem Cells Cloning; 2018; 11():55-67. PubMed ID: 30425534
[TBL] [Abstract][Full Text] [Related]
12. From de novo mutations to personalized therapeutic interventions in autism.
Brandler WM; Sebat J
Annu Rev Med; 2015; 66():487-507. PubMed ID: 25587659
[TBL] [Abstract][Full Text] [Related]
13. The genetics of autism.
Muhle R; Trentacoste SV; Rapin I
Pediatrics; 2004 May; 113(5):e472-86. PubMed ID: 15121991
[TBL] [Abstract][Full Text] [Related]
14. Potential benefits and limits of psychopharmacological therapies in pervasive developmental disorders.
Molteni M; Nobile M; Cattaneo D; Radice S; Clementi E
Curr Clin Pharmacol; 2014; 9(4):365-76. PubMed ID: 24050744
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, United States, 2006.
;
MMWR Surveill Summ; 2009 Dec; 58(10):1-20. PubMed ID: 20023608
[TBL] [Abstract][Full Text] [Related]
16. Autism: an emerging 'neuroimmune disorder' in search of therapy.
Theoharides TC; Kempuraj D; Redwood L
Expert Opin Pharmacother; 2009 Sep; 10(13):2127-43. PubMed ID: 19640207
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic properties of mesenchymal stem cells for autism spectrum disorders.
Gesundheit B; Ashwood P; Keating A; Naor D; Melamed M; Rosenzweig JP
Med Hypotheses; 2015 Mar; 84(3):169-77. PubMed ID: 25592283
[TBL] [Abstract][Full Text] [Related]
18. The use of iPSC technology for modeling Autism Spectrum Disorders.
Russo FB; Brito A; de Freitas AM; Castanha A; de Freitas BC; Beltrão-Braga PCB
Neurobiol Dis; 2019 Oct; 130():104483. PubMed ID: 31129084
[TBL] [Abstract][Full Text] [Related]
19. Pharmaceuticals and Stem Cells in Autism Spectrum Disorders: Wishful Thinking?
Sivanesan S; Tan A; Jeyaraj R; Lam J; Gole M; Hardan A; Ashkan K; Rajadas J
World Neurosurg; 2017 Feb; 98():659-672. PubMed ID: 27725300
[TBL] [Abstract][Full Text] [Related]
20. Long term beneficial effect of neurotrophic factors-secreting mesenchymal stem cells transplantation in the BTBR mouse model of autism.
Perets N; Segal-Gavish H; Gothelf Y; Barzilay R; Barhum Y; Abramov N; Hertz S; Morozov D; London M; Offen D
Behav Brain Res; 2017 Jul; 331():254-260. PubMed ID: 28392323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
